Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effect of Nanocurcumin Supplementation on the Severity of Symptoms and Length of Hospital Stay in Patients With Covid-19: A Randomized Double-Blind Placebo-Controlled Trial Publisher Pubmed



Honarkar Shafie E1 ; Taheri F1 ; Alijani N2 ; Okhovvat AR3 ; Goudarzi R1 ; Borumandnia N4 ; Aghaghazvini L5 ; Rezayat SM6 ; Jamalimoghadamsiahkali S7 ; Hosseinzadehattar MJ1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Infectious Disease, Shariati Hospital, Tehran university of medical sciences, Tehran, Iran
  3. 3. Central Herbarium, Tehran University, Tehran, Iran
  4. 4. Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Department of Radiology, Shariati hospital, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Phytotherapy Research Published:2022


Abstract

It has been more than a year since the outbreak of COVID-19, and it is still the most critical issue of the healthcare system. Discovering effective strategies to treat infected patients is necessary to decrease the mortality rate. This study aimed to determine the effects of nanocurcumin on the severity of symptoms and length of hospital stay (LOS) in COVID-19 patients. Forty-eight COVID-19 patients were randomly assigned into nanocurcumin (n = 24) and placebo (n = 24) groups receiving 160 mg/day nanocurcumin or placebo capsules for 6 days. Mean differences of O2 saturation were significantly higher in patients who received nanocurcumin supplements (p = 0.02). Also, nanocurcumin treatment significantly reduced the scores of domains 3 and 4 and the total score of Wisconsin Upper Respiratory System Survey (WURSS-24), indicating milder symptoms in the treatment group (p = 0.01, 0.03, and 0.01 respectively). Besides, the LOS in curcumin groups was lower than in the placebo group, although the difference was not statistically significant (6.31 ± 5.26 vs. 8.87 ± 8.12 days; p = 0.416). CBC/differentiate, hs-CRP level and the pulmonary involvement in CT scan were not different between the two groups. As nanocurcumin can be effective in increasing O2 saturation and reducing the severity of symptoms in COVID-19 patients, it could probably be used as a complementary agent to accelerate the recovery of patients. © 2022 John Wiley & Sons Ltd.
Experts (# of related papers)
Other Related Docs
10. Curcumin: A New Candidate for Melanoma Therapy?, International Journal of Cancer (2016)
12. Pharmacological Activities of Turmerones, Current Medicinal Chemistry (2025)
16. Protective Effects of Curcumin Against Traumatic Brain Injury, Biomedicine and Pharmacotherapy (2022)
18. Advances in Immunotherapy for Covid-19: A Comprehensive Review, International Immunopharmacology (2021)
23. Clinical Manifestations of Covid-19, Advances in Experimental Medicine and Biology (2021)
24. The Role of Medical Imaging in Covid-19, Advances in Experimental Medicine and Biology (2021)
36. Ct-Severity Score in Covid-19 Patients: For Whom Is It Applicable Best?, Caspian Journal of Internal Medicine (2022)
42. Neuroprotective Agents in the Intensive Care Unit, Journal of Pharmacopuncture (2018)